SWA
ACTU

SFMG Wealth Advisors’s Actuate Therapeutics ACTU Stock Holding History

SFMG Wealth Advisors’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.5K Hold
33,000
– – ﹤0.01% 338
2026
Q1 		$90.4K Buy
33,000
+13,000
+65% +$53.9K 0.01% 313
2025
Q4 		$122K Buy
20,000
+3,000
+18% +$20.6K 0.01% 298
2025
Q3 		$114K Buy
17,000
+2,450
+17% +$17.8K 0.01% 302
2025
Q2 		$88.9K Buy
14,550
+3,550
+32% +$31K 0.01% 274
2025
Q1 		$74.5K Buy
+11,000
New +$88.3K 0.01% 274

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $306M AUM 15.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

SFMG Wealth Advisors's ACTU Position: Q2 2026 in Review

SFMG Wealth Advisors held its Actuate Therapeutics (ACTU) position steady in Q2 2026 at 33,000 shares worth $50.5K. The position accounts for ﹤0.01% of the portfolio, ranked #338.

SFMG Wealth Advisors first reported a position in ACTU in Q1 2025 and has held it in 6 quarters since. The position peaked at $122K in Q4 2025. 63 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • SFMG Wealth Advisors held 33,000 shares of Actuate Therapeutics worth $50.5K as of Q2 2026.
  • SFMG Wealth Advisors left its Actuate Therapeutics share count unchanged in Q2 2026.
  • Actuate Therapeutics made up ﹤0.01% of SFMG Wealth Advisors's portfolio in Q2 2026, its #338 holding.
  • SFMG Wealth Advisors first reported a position in Actuate Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • SFMG Wealth Advisors's Actuate Therapeutics position peaked at $122K in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on SFMG Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.